Metabolic syndrome associated with HIV and highly active antiretroviral therapy

Giuseppe Barbaro, Gianluca Iacobellis

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The introduction of highly active antiretroviral therapy (HAART) has significantly improved the clinical outcome of HIV disease with increased survival rates. However, some HAART regimens, especially those including protease inhibitors, have been shown to cause in a high proportion of HIV-infected patients metabolic (dyslipidemia, insulin resistance) and somatic (lipodystrophy/lipoatrophy) changes that are associated with an increased risk of cardiovascular disease (coronary artery disease and stroke). The pathogenesis of HAART-associated metabolic syndrome and of its atherogenic profile is complex, and several factors are involved, including direct effects of HAART on lipid metabolism, endothelial and adipocyte cell function, activation of proinflammatory cytokines, and mitochondrial dysfunction. A better understanding of the molecular mechanisms responsible for this syndrome will lead to the discovery of new drugs that will reduce the incidence of lipodystrophy and related metabolic complications in HIV-infected patients facing long-term HAART.

Original languageEnglish
Pages (from-to)37-42
Number of pages6
JournalCurrent Diabetes Reports
Volume9
Issue number1
DOIs
StatePublished - Feb 16 2009
Externally publishedYes

Fingerprint

Highly Active Antiretroviral Therapy
HIV
Lipodystrophy
Drug Discovery
Dyslipidemias
Protease Inhibitors
Lipid Metabolism
Adipocytes
Insulin Resistance
Coronary Artery Disease
Cardiovascular Diseases
Survival Rate
Endothelial Cells
Stroke
Cytokines
Incidence

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Metabolic syndrome associated with HIV and highly active antiretroviral therapy. / Barbaro, Giuseppe; Iacobellis, Gianluca.

In: Current Diabetes Reports, Vol. 9, No. 1, 16.02.2009, p. 37-42.

Research output: Contribution to journalArticle

@article{6c459f7ca110416494b1203bacf27304,
title = "Metabolic syndrome associated with HIV and highly active antiretroviral therapy",
abstract = "The introduction of highly active antiretroviral therapy (HAART) has significantly improved the clinical outcome of HIV disease with increased survival rates. However, some HAART regimens, especially those including protease inhibitors, have been shown to cause in a high proportion of HIV-infected patients metabolic (dyslipidemia, insulin resistance) and somatic (lipodystrophy/lipoatrophy) changes that are associated with an increased risk of cardiovascular disease (coronary artery disease and stroke). The pathogenesis of HAART-associated metabolic syndrome and of its atherogenic profile is complex, and several factors are involved, including direct effects of HAART on lipid metabolism, endothelial and adipocyte cell function, activation of proinflammatory cytokines, and mitochondrial dysfunction. A better understanding of the molecular mechanisms responsible for this syndrome will lead to the discovery of new drugs that will reduce the incidence of lipodystrophy and related metabolic complications in HIV-infected patients facing long-term HAART.",
author = "Giuseppe Barbaro and Gianluca Iacobellis",
year = "2009",
month = "2",
day = "16",
doi = "10.1007/s11892-009-0008-7",
language = "English",
volume = "9",
pages = "37--42",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Metabolic syndrome associated with HIV and highly active antiretroviral therapy

AU - Barbaro, Giuseppe

AU - Iacobellis, Gianluca

PY - 2009/2/16

Y1 - 2009/2/16

N2 - The introduction of highly active antiretroviral therapy (HAART) has significantly improved the clinical outcome of HIV disease with increased survival rates. However, some HAART regimens, especially those including protease inhibitors, have been shown to cause in a high proportion of HIV-infected patients metabolic (dyslipidemia, insulin resistance) and somatic (lipodystrophy/lipoatrophy) changes that are associated with an increased risk of cardiovascular disease (coronary artery disease and stroke). The pathogenesis of HAART-associated metabolic syndrome and of its atherogenic profile is complex, and several factors are involved, including direct effects of HAART on lipid metabolism, endothelial and adipocyte cell function, activation of proinflammatory cytokines, and mitochondrial dysfunction. A better understanding of the molecular mechanisms responsible for this syndrome will lead to the discovery of new drugs that will reduce the incidence of lipodystrophy and related metabolic complications in HIV-infected patients facing long-term HAART.

AB - The introduction of highly active antiretroviral therapy (HAART) has significantly improved the clinical outcome of HIV disease with increased survival rates. However, some HAART regimens, especially those including protease inhibitors, have been shown to cause in a high proportion of HIV-infected patients metabolic (dyslipidemia, insulin resistance) and somatic (lipodystrophy/lipoatrophy) changes that are associated with an increased risk of cardiovascular disease (coronary artery disease and stroke). The pathogenesis of HAART-associated metabolic syndrome and of its atherogenic profile is complex, and several factors are involved, including direct effects of HAART on lipid metabolism, endothelial and adipocyte cell function, activation of proinflammatory cytokines, and mitochondrial dysfunction. A better understanding of the molecular mechanisms responsible for this syndrome will lead to the discovery of new drugs that will reduce the incidence of lipodystrophy and related metabolic complications in HIV-infected patients facing long-term HAART.

UR - http://www.scopus.com/inward/record.url?scp=59849124169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849124169&partnerID=8YFLogxK

U2 - 10.1007/s11892-009-0008-7

DO - 10.1007/s11892-009-0008-7

M3 - Article

C2 - 19192423

AN - SCOPUS:59849124169

VL - 9

SP - 37

EP - 42

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 1

ER -